Skeletalis initially targets osteoporosis with bone-targeted drug delivery designed to minimize systemic exposure.
Precision medicine startup Skeletalis has secured an $8 million funding round to advance new treatments for musculoskeletal diseases. The funding is intended to advance the development of its small molecule osteoporosis drug candidate towards clinical trials.
Solving musculoskeletal conditions is key to extending healthy longevity and sustaining functional independence in an aging population. Boston-based Skeletalis is initially focused on osteoporosis, a disease characterized by plummeting bone density. Alongside the progressive muscle loss known as sarcopenia, these conditions are key drivers of frailty and dependency, with osteoporotic fractures, such as a hip fracture, representing a catastrophic event for older adults that carries a high risk of disability, loss of independence and mortality.
Osteoporosis currently affects over 10 million adults in the United States, with a substantial majority being post-menopausal women. The disease is a higher risk for women, who typically have smaller, less dense bones than men, and can experience accelerated bone loss after menopause when estrogen levels drop. According to Skeletalis, the current standard of care for osteoporosis has been limited by a difficult trade-off for patients: efficacy at the potential cost of safety.
“Osteoporosis treatment is ripe for innovation,” said Skeletalis founder and CEO Ben Swanson, whose research on bone-targeted therapeutics at the University of Michigan led to the formation of the company. “Current therapies are limited by serious side effects that compromise safety, adherence, and long-term efficacy.”
Skeletalis has developed a bone-targeted small-molecule delivery platform designed to deliver a potent, localized disease-modulating therapy directly to the skeleton, specifically targeting sites of active bone loss and thereby minimizing systemic drug exposure. By re-engineering how osteoporosis drugs engage their target, the company seeks to develop a treatment that can prevent fractures and preserve bone mineral density without the significant safety concerns that have traditionally hampered long-term efficacy and tolerability. The company’s goal is to disarm the cells that drive pathological bone loss while preserving the body’s natural bone renewal process.
“We’re rethinking osteoporosis therapy from the ground up by selectively disarming the cells that drive pathological bone loss while preserving natural bone renewal,” Swanson told us. “By fusing decades of bone biology insights with a precision, bone-targeted approach, our team brings together the experts who helped define this field over the last 30 years to build what comes next.”
The funding round, led by Pillar VC and included participation from KdT Ventures, age1, and Slocum Management, comes amid recent shifts in regulatory policy, which have opened the door for new approaches in bone health solutions.
“The need for better treatments has been apparent for a long time, and while complex regulatory requirements previously prohibited new approaches, they have now shifted to become a tailwind for anyone trying to bring new medicines to patients,” said Pillar VC partner Thomas de Vlaam. “With the FDA’s landmark FNIH-ASBMR SABRE decision recognizing bone mineral density as a registrational endpoint for fracture prevention, the path is finally open for faster, smarter osteoporosis drug development.”
While the company’s immediate focus is on post-menopausal osteoporosis, Skeletalis indicates its approach also has potential applications in other degenerative bone diseases.
